Immune Design (IMDZ) Return on Assets ROA from the fourth quarter of 2018 to fourth quarter of 2017 and for the year 2018, Average High and Low, Fundamental Ratios from Dec 31 2018 to Dec 31 2017 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Immune Design Corp.  (IMDZ)


Immune Design's ROA from the fourth quarter of 2018 to the fourth quarter of 2017 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Immune Design's ROA in the fourth quarter of 2018?
Immune Design Corp. recorded a cumulative net loss of $-55 million during 12 months ending in the fourth quarter of 2018, resulting in a negative return on assets (ROA) of -46.19%.

However, within the Healthcare sector 539 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2018 from 4199 to 4790.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter		 (Jun 30 2018)
II. Quarter		 (Mar 31 2018)
I. Quarter		 (Dec 31 2017)
IV. Quarter
Y / Y Total Assets Change -34.37 % 44.98 % 37.26 % 35.47 % 41.79 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -55 -53 -53 -53 -52
Return On Assets (TTM) -46.19 % -40.33 % -42.69 % -45.88 % -49.08 %
IMDZ's Total Ranking # 4790 # 4199 # 4285 # 4395 # 4626
Total Assets (TTM) in million 101 113 125 135 154
Seq. Total Assets Change -10.8 % -9.26 % -7.82 % -12.04 % 97.05 %
Seq. Net Income Change - - - - -

IMDZ's 5 Years Annual ROA >> Back to IMDZ Management Effectiveness >> Compare IMDZ ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 263
Sector # 540
Overall # 4569

Return On Assets Statistics
High Average Low
-14.56 %
-38.08 %
-56.69 %
  (Sep 30 2017)





Financial Statements
Immune Design's Assets $ 101 million IMDZ's Balance sheet
Immune Design's Income $ -14 million Quarterly IMDZ's Income Statement
IMDZ's Income by Division See IMDZ's Income by Division



Annual Return On Assets (Dec 31 2018)
FY 2018		 (Dec 31 2017)
FY 2017		 (Dec 31 2016)
FY 2016		 (Dec 31 2015)
FY 2015		 (Dec 31 2014)
FY 2014
Y / Y Total Assets Change -34.37 % 34.36 % -1.42 % 48.18 % -
Total Assets in million 101 154 114 116 78
Y / Y Net Income Change - - - - -
Net Income in million -55 -52 -54 -39 -34
Annual Return On Assets -54.24 % -33.71 % -46.75 % -33.96 % -43.57 %

IMDZ's 5 Years Annual ROA >> Back to IMDZ Management Effectiveness >> Compare IMDZ ROA to its Competitors



More Return On Assets Ratios
IMDZ's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IMDZ's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IMDZ's Competitors
Subscribers only: Roa for Immune Design's Suppliers
Subscribers only: Return On Assets for IMDZ's Customers

You may also want to know
IMDZ's Roi IMDZ's Inventory Turnover Ratio IMDZ's Growth Rates IMDZ's Dividend Comparisons
IMDZ's Profitability Ratios IMDZ's Asset Turnover Ratio IMDZ's Dividend Growth
IMDZ's Roe IMDZ's Valuation Ratios IMDZ's Financial Strength Ratios IMDZ's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2018, within Healthcare Sector ROA

Date modified: 2026-09-05T14:00:45+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.